本帖最后由 老马 于 2012-1-13 21:20 编辑
, i5 E5 ^: M3 @& V$ U3 Y$ g9 E* D3 d ?! h3 f
爱必妥和阿瓦斯丁的比较" i% s, i$ m& ?4 F: \, O
2 \/ L* F5 G* S& R0 s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 h) n6 a0 Q* X( c6 ?1 B' j3 S
" b+ E' U P' w% S
" N2 P4 X2 w3 L8 W( O
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/& h, U* l) Q9 _3 y0 W
==================================================
& w; [! p4 ~/ m7 o6 a# P5 I4 FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" E1 C: ]9 b3 l1 UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, f K/ O; ~7 CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.5 X2 n, {5 r+ K6 Y
|
显身卡
0 y1 n% ]8 I) o) X
